López-Gómez S, Del Palacio A, Van Cutsem J, Soledad Cuétara M, Iglesias L, Rodriguez-Noriega A
Hospital 12 de Octubre, Madrid, Spain.
Int J Dermatol. 1994 Oct;33(10):743-7. doi: 10.1111/j.1365-4362.1994.tb01525.x.
Tinea capitis is a fungal infection in which topical therapy is often unsuccessful. Griseofulvin has been considered to be a first-line therapy. Other antifungal agents are the azole derivatives. Among these, itraconazole was compared with griseofulvin in children in a double-blind study.
Thirty-four children and one adult with clinical signs and symptoms of tinea capitis and with positive culture and microscopy for dermatophytes have been included in a double-blind comparison between itraconazole, 100 mg daily, and ultramicronized griseofulvin, 500 mg daily. Both drugs were given for 6 consecutive weeks. The final evaluation was made 8 weeks after the end of treatment to allow the hairs to regrow. Seventeen itraconazole- and 15 griseofulvin-treated patients received the complete 6-week treatment course. Fifteen of these 17 itraconazole patients and 14 of the 15 griseofulvin patients had infections caused by Microsporum canis. Fifteen of 17 patients were cured by itraconazole (88%) and 15 of 17 patients by griseofulvin (88%). One of the patients who discontinued griseofulvin therapy after 4 weeks was clinically and mycologically cured. Two of the original 17 griseofulvin patients discontinued therapy because of vomiting. None of the itraconazole-treated children experienced side effects.
Itraconazole is the first azole derivate that matches griseofulvin for the treatment of tinea capitis in children. The drug also appears to be better tolerated than griseofulvin.
头癣是一种真菌感染，局部治疗往往不成功。灰黄霉素一直被认为是一线治疗药物。其他抗真菌药物是唑类衍生物。其中，在一项双盲研究中对儿童患者比较了伊曲康唑和灰黄霉素。
34名儿童和1名成人，有头癣的临床症状和体征，且皮肤真菌培养和显微镜检查呈阳性，参与了一项双盲比较研究，比较每日服用100mg伊曲康唑与每日服用500mg超微粒化灰黄霉素的疗效。两种药物均连续服用6周。在治疗结束8周后进行最终评估，以便毛发重新生长。17名接受伊曲康唑治疗和15名接受灰黄霉素治疗的患者完成了6周的完整疗程。这17名伊曲康唑治疗患者中的15名和15名灰黄霉素治疗患者中的14名感染由犬小孢子菌引起。17名患者中有15名被伊曲康唑治愈（88%），17名患者中有15名被灰黄霉素治愈（88%）。1名在4周后停止灰黄霉素治疗的患者在临床和真菌学上均已治愈。最初17名灰黄霉素治疗患者中有2名因呕吐而停止治疗。接受伊曲康唑治疗的儿童均未出现副作用。
伊曲康唑是第一种在治疗儿童头癣方面与灰黄霉素效果相当的唑类衍生物。该药物的耐受性似乎也比灰黄霉素更好。
